Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Auxilium Pharmaceuticals has temporarily suspended dosing in its phase III trials for AA4500 for the treatment of Dupuytren's contracture, in response to a failure of material in some vials of AA4500 for use in the trials.
Subscribe to our email newsletter
The company is conducting an investigation to determine the root cause of this failure and believes that it is likely related to the higher than expected moisture content within the vial. Based on tests conducted, the company believes that the issue is related to either the lyophilization process or the equipment.
Auxilium stated that it has not received any reports of adverse reactions from the ongoing phase III trials and that the clinical trial investigators would continue to monitor patients already dosed in accordance with the trial protocols.
“We know that the manufacture of biologics is complex and our team of experts will endeavor to complete the root cause investigation as soon as possible in order to implement corrective actions so that we can resume the phase III trials,” said Armando Anido, CEO and president.